Document is current
Any future updates will be listed below
-
Authors
Miller, Tyler E. https://orcid.org/0000-0002-1269-1895
El Farran, Chadi A. https://orcid.org/0000-0002-9374-103X
Couturier, Charles P. https://orcid.org/0000-0001-8015-7160
Chen, Zeyu
D’Antonio, Joshua P.
Verga, Julia
Villanueva, Martin A. https://orcid.org/0000-0002-7630-1403
Gonzalez Castro, L. Nicolas https://orcid.org/0000-0001-7699-5188
Tong, Yuzhou Evelyn https://orcid.org/0000-0003-2652-5828
Saadi, Tariq Al https://orcid.org/0000-0002-9674-5175
Chiocca, Andrew N.
Zhang, Yuanyuan
Fischer, David S.
Heiland, Dieter Henrik
Guerriero, Jennifer L. https://orcid.org/0000-0002-2104-5457
Petrecca, Kevin https://orcid.org/0000-0002-8140-6402
Suva, Mario L. https://orcid.org/0000-0001-9898-5351
Shalek, Alex K. https://orcid.org/0000-0001-5670-8778
Bernstein, Bradley E. https://orcid.org/0000-0002-5726-6278
- License Information
-
More Information
Article History
Received: 9 October 2023
Accepted: 10 January 2025
First Online: 26 February 2025
Competing interests
: T.E.M. has financial interests in Reify Health, Care Access Research and Telomere Diagnostics. C.P.C. has financial interest in Axoft. L.N.G.C. receives consulting fees from Elsevier, Oakstone Publishing, Prime Education, BMJ Best Practice and Servier, and research funding from Merck & Co (to the Dana-Farber Cancer Institute). J.L.G. is consultant and serves on the scientific advisory board of Array BioPharma, AstraZeneca, BD Biosciences, Carisma, Codagenix, Duke Street Bio, GlaxoSmithKline, Kowa, Kymera, OncoOne and Verseau Therapeutics, and receives research support from Array BioPharma/Pfizer, Eli Lilly, GlaxoSmithKline and Merck. M.L.S. is an equity holder, scientific co-founder and advisory board member of Immunitas Therapeutics. A.K.S. receives compensation for consulting and/or scientific advisory board membership from Honeycomb Biotechnologies, Cellarity, Ochre Bio, Relation Therapeutics, FL86/Quotient Therapeutics, Parabalis Medicines, Passkey Therapeutics, IntrECate Biotherapeutics, Danaher, Senda Biosciences and Dahlia Biosciences that is unrelated to this work. B.E.B. has financial interests in Fulcrum Therapeutics, HiFiBio, Arsenal Biosciences, Chroma Medicine and Cell Signaling Technologies. The other authors declare no competing interests.
